Navigation Links
William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
Date:1/7/2008

SOUTH SAN FRANCISCO, Calif., Jan. 7 /PRNewswire/ -- Hyperion Therapeutics, Inc., a privately-held biopharmaceutical company focused on the development and commercialization of hepatology and gastrointestinal therapies that address orphan and underserved patient populations with unmet medical needs, today announced that William R. Ringo has been elected to its Board of Directors and will serve as Chairman.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070905/AQW076LOGO)

Mr. Ringo brings to the Hyperion Board thirty-five years of experience working with public and private pharmaceutical and biotechnology companies. He is the former President and Chief Executive Officer of Abgenix, Inc., which sold for $2.7 billion to Amgen in April 2006. In 2001 he retired from Eli Lilly & Company as Product Group President for Oncology and Critical Care. During his twenty-eight years at Eli Lilly & Company, Mr. Ringo held a number of senior positions including President of Internal Medicine Products, President of Infectious Diseases Business Unit, and Vice President of Sales and Marketing for U.S. Pharmaceuticals. He is currently an Executive-in-Residence at Sofinnova Ventures and serves as Chairman of the Board of Directors at Intermune and a member of the Board of Directors of Inspire Pharmaceuticals, Allos Therapeutics, Alvine Pharmaceuticals, Portola Pharmaceuticals, and BioCrossroads, a not for profit organization. Mr. Ringo holds a B.S. and an M.B.A. from the University of Dayton.

"We are very excited to have Bill join Hyperion as our Chairman," said Chris Rivera, President and CEO. "Having someone with his experience and track record in the industry on our Board should help us continue to build value in Hyperion, as well as execute our long-term strategy."

About Hyperion Therapeutics

Hyperion Therapeutics is a specialty therapeutics company focused on becoming a global leader in hepatology and gastrointestinal (GI) therapeutic programs and products that address orphan and underserved patient populations with unmet medical needs. The company has assembled a seasoned executive team with extensive industry experience developing and commercializing specialty pharmaceutical products. Hyperion is headquartered in South San Francisco, CA. For additional information, visit: http://www.hyperiontx.com.


'/>"/>
SOURCE Hyperion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Olympic Gold Medalist Kristi Yamaguchi Joins American Lung Association of Michigan to Address Seriously Low Vaccination Rates; Urge Metro-Detroiters to Get Immunized This Season
3. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
4. Actress and Mother Jennifer Garner Joins American Lung Association to Encourage Americans to Get an Influenza Vaccination
5. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
6. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
7. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
8. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of GT4P in Patients With Urea Cycle Disorders
9. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
10. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 ... completion of an alternative public offering (APO). This was ... operating company, Valeritas, Inc. and a private placement of ... at $5.00 per share. Under the terms ... 3, 2016, Valeritas Holdings, Inc. will trade on the ...
(Date:5/4/2016)... May 4, 2016 ... the  "Global Acute lymphocytic Leukemia Market and ... their offering.       (Logo: ... Lymphocytic Leukemia Market and Competitive Landscape Highlights ... Leukemia pipeline products, Acute Lymphocytic Leukemia epidemiology, ...
(Date:5/3/2016)... , May 3, 2016  As a teenager, ... contracted rheumatic fever, which damaged his heart. He continued ... But by June 2013, Shepherd,s heart was giving out ... death. On June 20, 2013, the Mesa, ... Artificial Heart (TAH-t). Like a heart transplant, the SynCardia ...
Breaking Medicine Technology:
(Date:5/4/2016)... Texas (PRWEB) , ... May 04, 2016 , ... May ... awareness in people across the United States. Dermatologist Dr. Ellen Turner is encouraging her ... dermatology experts’ advice and focus on skin safety and health now and in the ...
(Date:5/4/2016)... ... May 04, 2016 , ... Dr. Elyson and Dr. Assili, ... surgery at their office. Wisdom tooth removal, a common dental procedure, is performed for ... often are improperly erupted, resulting in risks of complications. By providing wisdom tooth removal ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nordic Naturals announces another ... metabolic health. This synergistic combination of omega-3 fatty acids and potent antioxidants contains ... of reduced glutathione and 200 mg of N-Acetylcysteine (NAC). , Each nutrient ...
(Date:5/4/2016)... ... May 04, 2016 , ... Francesca Loparco, Co-Founder of Queen ... forever with a same-day LASIK procedure at Christenbury Eye Center. The entrepreneur ... Christenbury performed her surgery the same day as her in-office consultation and eye exam. ...
(Date:5/4/2016)... ... May 04, 2016 , ... Pharmacy ... announced that it was chosen as the Pharmaceutical News Provider of the Year ... awards acknowledge the hard work and dedication of community members who strive to ...
Breaking Medicine News(10 mins):